期刊文献+

RhoC及MMP-9在原发性肝细胞癌中的表达水平与术后复发关系的研究 被引量:3

Relation between the expression of RhoC and MMP-9 protein with the recurrence after hepatectomy in the patients with hepatocellular carcinoma
下载PDF
导出
摘要 目的:探讨RhoC及基质金属蛋白酶-9(metrix metalloproteinases,MMP-9)蛋白在原发性肝细胞肝癌(以下称肝癌)发生、发展、转移及术后复发过程中的作用。方法:采用免疫组织化学染色检测43例肝癌患者术后癌灶和癌周标本及25例肝硬化、23例正常肝脏标本中两种蛋白的表达情况,分析两种蛋白的表达与肝癌病理特点的关系及两者表达的相关性,采用COX比例风险模型进行肝癌术后复发风险多因素分析。结果:RhoC在肝癌组与癌旁组、肝硬化组、正常肝组及癌旁组与正常肝组表达程度差异有统计学意义(P<0.05);MMP-9在肝癌组与癌旁组、肝硬化组、正常肝组表达程度差异有统计学意义(P<0.05)。RhoC与MMP-9在肝癌癌灶中表达存在相关性,且为正相关(rs'=0.495,P<0.01)。RhoC阴性组的中位生存时间46个月,阳性组中位生存时间为20个月;MMP-9阴性组的中位生存时间49个月,阳性组的中位生存时间25个月;RhoC及MMP-9都为阴性,中位生存时间56个月;RhoC或MMP-9为阴性,中位生存时间39个月;RhoC及MMP-9都为阳性,中位生存时间19个月。COX比例风险分析模型分析认为:肿瘤侵及门静脉(包括微转移灶)、淋巴结转移、RhoC及MMP-9阳性表达分别为肿瘤术后复发的独立危险因素。结论:RhoC蛋白在肝癌的早期开始起作用,且RhoC蛋白及MMP-9蛋白的异常高表达提示肿瘤恶性程度高,术后复发率高,指导临床术后预防性化学治疗有一定指导意义。 Objective: To explore the value of ras homologous C (RhoC) and matrix metalloproteinase-9 (MMP-9) protein in the occurrence, development, metastasis and recurrence of primary hepatocellular carcinoma (HCC). Methods: To investigate the expression of the two proteins in the specimans of 43 HCC, 43 paracancer, 25 cirrhosis and 23 normal liver tissues by immunohistochemistry, and analyse the relation between the expression and the pathologic features of HCC and the expression among the different tissues, including the correlation between the two proteins. COX proportion hazard model was used to estimate the recurrence risk factors. Results: The expression of RhoC protein in specimans of HCC was significantly higher than paracancer, cirrhosis and normal liver tissues, the difference between paracancer and normal liver tissues was also significant. The expression of MMP-9 protein in specimens of HHC was significantly higher than paracancer, cirrhosis and normal liver tissues. There was positive correlation between the expressions of the two proteins. (rs=0.495 P〈0.01) .The median survival time in negative group of RhoC protein was 46.00 months and the positive one was 20.00 months. The median survival time in negative one of MMP-9 protein was 49.00 months and the positive one was 25.00 months. The median survival time in conegative group of RhoC and MMP-9 protein was 56.00 months, the median survival time of single negative group of RhoC or MMP-9 protein was 39.00 months, the median survival time in copositive group of RhoC and MMP-9 protein was 19.00 months. The COX proportion hazard model revealed that portal vein invasion, lymph node metastasis and expression of RhoC and MMP-9 protein were the independent recurrence risk factors. Conclusion: RhoC protein played a role at the early stage of the HCC, and the expression of RhoC and MMP-9 protein in HCC tissue was closely correlation to the recurrence after hepatectomy, which could induct the chemoprophylaxis.
出处 《中国现代普通外科进展》 CAS 2008年第4期332-335,351,共5页 Chinese Journal of Current Advances in General Surgery
关键词 肝细胞 RHOC蛋白 基质金属蛋白酶类 复发 Carcinoma, hepatocellar ·RhoC protein ·Metrix metalloproteinases · Recurrence
  • 相关文献

参考文献8

  • 1吴孟超.肝癌外科治疗的近期进展[J].中国普外基础与临床杂志,2006,13(2):125-128. 被引量:71
  • 2汤钊猷.试论原发性肝癌复发转移的研究[J].中华实验外科杂志,1999,16(6):485-486. 被引量:20
  • 3Kleer CG, Van Golen KL,Zhang Y, et al. Characterization of Rhoc expression in benign and malignant breast disease:a potential new marker for small breast carcinomas ability [J]. Am J pathol, 2002, 160(2):579-584.
  • 4Chardin P, Madaule P, Tavitian A.Coding sequence of human rho cDNAs clone 6 and clone 9[J]. Nucleic Acid Res,1988, 16(6):2717.
  • 5郑岩松,吕新生,曾永毅,林永堃,林旭.乙肝病毒X基因对肝癌细胞表达RhoC的影响[J].中国普通外科杂志,2006,15(12):923-926. 被引量:4
  • 6Powell WC, Knox JD, Navre M, et al. Expression of metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficientmice [J]. Cancer Res, 1993,53 (2):417-428.
  • 7Frederiok J, Bhada S, Subbiah M, et al. Multifunction a role for fetuin (fetal protein) in lipid transport[J]. Faseb J, 1991,5(7):2145-2149.
  • 8Arii S, Mise M, Harada T, et al. Overexpression of MMP-9 gene in hepatocellular carcinoma with invasive protential [J]. Hepatology, 1996, 24(2):316-319.

二级参考文献17

  • 1El-Scrag HB. Hepatocellular carcinoma: an epidemiologic view[J]. J Clin Gastroenterol, 2002,35(5 Suppl 2): S72
  • 2Lok AS, McMahon BJ; Practice Cuidelines Committee, et al.Chronic hepatitis B: update of recommendations [J]. Hepatology, 2004,39(3):857
  • 3Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus [J]. Gastroenterology, 2004,126(1):81.
  • 4Hanazaki K, Kajikawa S, Shimozawa N, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma [J]. J Am Coll Surg, 2000,191(4):381
  • 5Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters[J]. Ann Surg, 2002,235 (4): 533
  • 6Yoo HY, Patt CH, Geschwind JF, et al. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time [J]. J Clin Oncol, 2003,21(23):4329
  • 7Schwartz JD, Schwartz M, Mandeli J, et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials [J]. Lancet Oncol, 2002,3(10):593.
  • 8Cougot D,Neuveut C,Buendia MA.HBV induced carcinogenesis[J].J Clin Virol,2005,34(1):S75 -78.
  • 9Ou DP,Tao YM,Chang ZG,et al.Hepatocellular carcinoma cells containing hepatitis B virus X protein have enhanced invasive potential conditionally[J].Dig Liver Dis,2006,38 (4):262-267.
  • 10Zhang X,Zhang H,Ye L.Effects of hepatitis B virus X protein on the development of liver cancer[J].J Lab Clin Med,2006,147(2):58 -66.

共引文献92

同被引文献22

  • 1田辉,刘贤锡,王善政.MMP-9、HPSE和VEGF-C蛋白表达在中老年人肺癌抗血管和抗淋巴管生成治疗中的意义[J].中国老年学杂志,2005,25(1):29-31. 被引量:3
  • 2陈卫中,倪宗瓒,潘晓平,刘元元,夏彦.用ROC曲线确定最佳临界点和可疑值范围[J].现代预防医学,2005,32(7):729-731. 被引量:208
  • 3郑莹,朱美英,程月华,朱云,邱永莉,王春芳,顾凯.上海市社区肝癌高危人群早发现干预效果的研究[J].肿瘤,2007,27(1):73-77. 被引量:14
  • 4Kew MC. Epidemiology of hepatocellular carcinoma[ J ]. Toxicology, 2002,27 (3) :35-38.
  • 5Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics 2002 [ J ]. CA Cancer J Clin,2005,55 ( 2 ) :74-108.
  • 6Purves LR,Merwe VE,Besohn L,et al. Variants of Afetomtein[ J]. Lancet, 1970,12(5 ) :460.
  • 7ada T,Nakano S,Takeda I,et al. Clinical utihty of lensculinaris ag- glutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma : special reference to imaging diagnosis[ J ]. J Hepato|, 1999,30 (2) : 125-130.
  • 8Okamura H, Tstutsi H, Komatsui H, et al. Cloning of a new cytokine that induces IFN-3, production by T cell [ J ]. Nature, 1995,378 ( 7 ) : 88-91.
  • 9Ushio S, Namba M, Okura T, et al. Cloning of the cDNA for human IFN-/-inducing factor, expression in Escherichi coli, and studies on the biological activities of the protein [ J ]. J Immunol, 1996, 156 ( 3 ) :42474279.
  • 10Subleski JJ, Hall VL, Back TC. Wilrtrout RH Enhanced anti - tumor response by divergent modulation of natural killer and natural killer T cells in the liver [ J ]. Cancer research, 2006,22 ( 1 ) : 131 - 135.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部